




**Department of Medical Physics**  
UNIVERSITY OF WISCONSIN – MADISON  
SCHOOL OF MEDICINE AND PUBLIC HEALTH

**RED**  
RADIOLOGICAL ENGINEERING  
& DESIGN LABORATORY


# FDA-Approved (and Upcoming) Dosimetry Software

**Bryan P. Bednarz**  
Associate Professor  
Department of Medical Physics  
Wisconsin Institute for Medical Research  
University of Wisconsin – Madison


AAPM Annual Meeting, San Antonio, TX July 18<sup>th</sup>, 2019



1



## Disclosures



I'm the co-founder and CSO of Voximetry, LCC a Middleton-based nuclear medicine dosimetry company.

Information for this talk based on:

- 75+ customer discovery interviews
- Recent “cold” calls/emails
- Desk research

7/18/2019 | AAPM Annual Meeting, San Antonio, TX | B.P. Bednarz
2

2



## Outline



- Background
- Current Dosimetry Workflows
- Customer Needs
- FDA-Cleared Dosimetry Products
- Upcoming Dosimetry Products
- Billing

3



## Background



When radiopharmaceutical therapy (RPT) fails to produce significant improvement in local control it is primarily due to:

- Tumor selectivity
- Limited radiation tolerance of normal tissues
- Tumor radiosensitivity
- Heterogeneous uptake within the tumor (i.e. heterogeneous dose)

4



## Background



When radiopharmaceutical therapy (RPT) fails to produce significant improvement in local control it is primarily due to:

- Tumor selectivity
- Limited radiation tolerance of normal tissues
- Tumor radiosensitivity
- Heterogeneous uptake within the tumor (i.e. heterogeneous dose)

**Patient-specific dosimetry can improve RPT outcomes**

5



## Background




EU directive 2013/59/EURATOM Article 56 states:


“For all medical exposure of patients for radiotherapeutic purposes, exposures of target volumes shall be individually planned and their delivery appropriately verified taking into account that doses to non-target volumes and tissues shall be as low as reasonably achievable and consistent with the intended radiotherapeutic purpose of the exposure”.

“‘radiotherapeutic’ means pertaining to radiotherapy, including nuclear medicine for therapeutic purposes”


6




7



8



9



10



## Customer Needs



- **Image Reconstruction**
  - Attenuation Correction
  - Scatter Correction
  - Resolution Recovery
- **Registration**
  - Rigid
  - Affine
  - Deformable
- **Segmentation**
  - Manual
  - Semi-automated
  - Automated
- **Kinetic Modeling**
  - Trapezoidal Integration
  - Curve Fitting
  - PK Modeling
- **Dose Calculation**
  - Phantom-based
  - Voxel-based
    - Local Energy Deposition
    - Dose Kernel or Voxel S-Value
    - Direct Monte Carlo
- **Biological Modeling**
  - BED
  - EUD

7/18/2019 | AAPM Annual Meeting, San Antonio, TX | B.P. Bednarz

11

11



## FDA-Cleared Dosimetry Software



Company	Product(s)	Image Reconstruction	Registration	Segmentation	Kinetic Modeling	Dose Calculation	Clearance
Hermes Medical Solutions	Hybrid3D™ SIRT	Vendor Neutral Attenuation Correction Scatter Correction Resolution Recovery	Multi-modality rigid and "focused" based	Semi-automated	Physical Decay	Local Energy Deposition – <sup>90</sup> Y	510(k) Clearance (July 2017)
	Hybrid Dosimetry™ OLINDA/EXM 2.0®				Exponential Bi-Exponential Trapezoidal	OLINDA 2.0 'Semi' Monte Carlo under FDA review	
MIMs	SurePlan™ LiverY90	Vendor Neutral Attenuation Correction Scatter Correction Resolution Recovery	Multi-modality rigid and deformable	Manual Semi-automated Automated	Physical Decay	Local Energy Deposition – <sup>90</sup> Y	510(k) Clearance (Nov. 2017) 510(k) Clearance (Dec. 2018)
	SurePlan™ MRT				Exponential Bi-Exponential Trapezoidal	Voxel S-Value – <sup>177</sup> Lu and <sup>131</sup> I	
Varian	Velocity™ RapidSphere	NA	Multi-modality rigid and deformable	Manual Semi-automated Automated	Physical Decay	Local Energy Deposition – <sup>90</sup> Y	510(k) Clearance (Feb. 2018)

NA = Not Available

7/18/2019 | AAPM Annual Meeting, San Antonio, TX | B.P. Bednarz

12

12



## FDA-Cleared Dosimetry Software



Company	Product(s)	Image Reconstruction	Registration	Segmentation	Kinetic Modeling	Dose Calculation	Clearance
<b>Mirada</b>	Simplicit90Y™ XD Nucl Med	NA	Multi-modality rigid and deformable	Manual Semi-automated Automated	Physical Decay	Local Energy Deposition – <sup>90</sup> Y	510(k) Clearance (Dec. 2018)
<b>Dosisoft</b>	PLANET® Dose	NA	Multi-modality rigid and deformable	Manual Semi-automated Automated	Physical Decay	Local Energy Deposition and Voxel S-Values – <sup>90</sup> Y	510(k) Clearance (Mar. 2019)

NA = Not Available

13



## Emerging Products



- Philips Healthcare Stratos (Part of Imalytics Research Workstation)
- Siemens Healthineers' Dosimetry Research Tool\*
- SurgicEye DosePlan
- Rapid, LLC
- Voximetry, Inc.

\*Investigational device not commercially available

14



## Reimbursement



### EBRT CPT® Planning Codes

77261, 77263, 77280,  
77290, 77293, 77295,  
77300, 77331, 77301,  
77338, 77306, 77307,  
77321, 77332, 77334,  
77336, 77370\*

### Nuclear Medicine CPT® Planning Codes

77370\*  
77300  
77295



\*Special medical radiation physics consultation (\$125.35)

15



## SAM Question # 1



1) The OLINDA/EXM software is now distributed by:

- a. Varian Medical Systems
- b. Hermes Medical Solutions
- c. Dosisoft
- d. MIM Software Inc.

16





## SAM Question # 1



1) The OLINDA/EXM software is now distributed by:

- a. Varian Medical Systems
- b. Hermes Medical Solutions
- c. Dosisoft
- d. MIM Software Inc.

**Answer: (b)**

Reference: Huizing et al. "Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review" EJNMMI Research (2018) 8:89



## SAM Question # 2



1) Commercial voxel-level dosimetry software is primarily being used to:

- a. Verify dose distributions from selective internal radiation therapy
- b. Perform treatment planning calculations for selective internal radiation therapy
- c. Verify dose distributions from systemically delivered RPT agents (e.g. Lutathera®)
- d. Perform treatment planning calculations for systemically delivered RPT agents (e.g. Lutathera®)



## SAM Question # 2



- 1) Commercial voxel-level dosimetry software is primarily being used to:
- a. Verify dose distributions from selective internal radiation therapy
  - b. Perform treatment planning calculations for selective internal radiation therapy
  - c. Verify dose distributions from systemically delivered RPT agents (e.g. Lutathera®)
  - d. Perform treatment planning calculations for systemically delivered RPT agents (e.g. Lutathera®)

**Answer: (a)**

Reference: Kafrouni et al. "Retrospective voxel-based dosimetry for assessing the body surface area model ability to predict delivered dose and radioembolization outcome" J Nucl Med. (2018) 59(8):1289-1295

19



## References



FDA Clearance notification letters for DOSIsoft, Mirada Medical Ltd., Varian Medical Systems, Inc, Hermes Medical Solutions AB, MIM Software Inc.

Kappadatch SC, "Yttrium-90 microsphere therapy planning and dose calculations", AAPM Annual Meetin 2011

McMeekin H. "Calculation methods in Hermes Medical Solution's dosimetry software", MRTDosimetry Workshop 2018

Jenkins L. "HERMES Dosimetry Software" 3<sup>rd</sup> MRTDosimetry Workshop 2015

Bose S. "Velocity™ 4.0", AAMD Spring Regional Meeting 2018

Velocity Feature Sheet

[https://www.varian.com/sites/default/files/resource\\_attachments/VelocityFeatureSheet\\_RAD\\_10569\\_June2018\\_Secured.pdf](https://www.varian.com/sites/default/files/resource_attachments/VelocityFeatureSheet_RAD_10569_June2018_Secured.pdf)

20

# Acknowledgements

## Acknowledgements

RED Lab Team	Jamey Weichert
Joseph Grudzinski	Renier Hernandez
Ian Marsh	Zach Morris
Andrew Shepard	Peter Carlson
Charlie Matrosic	Paul Sondel
David Adam	Mario Otto
Sydney Jupitz	Dana Baiu
Sabrina Hoffman	Lance Hall
Abby Besemer	Paul Harari
	Paul Wickre







# Thank You!

**Bryan P. Bednarz, Ph.D.**  
 Associate Professor  
 Department of Medical Physics  
 University of Wisconsin-Madison  
 1111 Highland Ave., L5-176  
 Madison, WI 53705-2275  
 o - (608) 262-5225  
 c - (734) 678-2346  
 bbednarz2@wisc.edu

21




22



23

23



24

24